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Abstract
Cancer incidence is progressively increasing in parallel with an increase in the rate of cancer survivors with the help of 
advanced treatment modalities. By the year 2010, it is estimated that one in every 250 persons will have survived a 
childhood malignancy. The increased rates of survival bring about complications related to reproductive health. Cytotoxic 
treatments due to chemo- and radiotherapy or bone marrow transplantation suppress or irreversibly harm not only female 
ovarian reserve but also male testicular sperm production. In this review, cryopreservation of gametes and gonads with 
fertility preservation options and indications prior to cancer treatments are discussed. (Turk J Hematol 2009; 26: 106-13)
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Özet
Kanser insidansındaki artışa paralel olarak, gelişen tedavi modalitelerinin yardımıyla, bu hastalıktan sağkalım oranları da her 
geçen gün artmaktadır. 2010 yılında her 250 kişiden birinin çocukluk çağı kanserlerinden tedavi olmuş bir birey olacağı 
hesaplanmaktadır. Sağkalım oranlarının artışı, üreme sağlığını etkileyen komplikasyonları da beraberinde getirmektedir. 
Yüksek kemoterapi ve radyoterapi ya da kemik iliği transplantasyonuna bağlı sitotoksik tedaviler gerek over rezervini, ger-
ekse testiküler sperm üretimini baskılayan ya da geri dünüşümsüz olarak hasara uğratan tedavi seçenekleridir. Bu derle-
mede, bahsedilen tedaviler öncesinde hastaların gonad ya da gametlerinin kriyoprezervasyonu ve kür sonrası fertilitenin 
geri kazandırılmasıyla ilgili seçenekler ve endikasyonlar ele alınmıştır. (Turk J Hematol 2009; 26: 106-13)
Anahtar kelimeler: Doğurganlığın korunması, kanser, kemoterapi, radyoterapi, kriyoprezervasyon
Geliş tarihi: 23 Aralık 2008  Kabul tarihi: 08 Nisan 2009Introduction
Cancer incidence is gradually increasing while deaths 
caused by malignant diseases decrease. When all female 
cancers are considered, despite an increase in the cancer 
incidence by 0.3% annually from 1987 to 1999, the death rates 
for all cancers combined decreased by 0.6% annually from 
1992 to 1999 as a result of improvements in current treatment 
modalities including surgical techniques, radiation therapy, 
multi-agent chemotherapy, and hematopoietic stem cell 
transplantation (HSCT) [1,2]. By 2010, one in every 250 
persons is estimated to have survived childhood malignancies. 
Thus, more patients survive cancer every year but face the 
challenging long-term side effects, especially related to their 
reproductive system. The risk of ovarian failure may increase 
up to nine-fold in female cancer survivors receiving 
cyclophosphamide-based combination chemotherapy [3,4], 
and ovarian failure is almost inevitable in patients undergoing 
preconditioning with chemoradiation before HSCT [5]. It is also 
reported that an ovarian radiation dose of more than 6 Gy 
usually results in permanent infertility [6]. Chemo-/radiotherapy 
sequelae may impair the quality of the pregnancy as well, with 
an increased risk of early pregnancy loss, premature labor, and 
low birth weight, even if the patients were not sterilized after 
treatments [7-9]. 
The introduction of assisted reproduction and its current 
worldwide utilization has resulted in the development of 
successful cryopreservation techniques for surplus embryos. 
The techniques created for embryo cryopreservation have 
further been applied to the unfertilized mature and immature 
human oocyte [10,11] and ovarian tissue [12-17]. Currently, 
embryo cryopreservation is the preferred method to preserve 
future fertility because of reasonable post-thaw survival, 
implantation, and delivery rates, if the patient has a life-partner 
or access to a sperm donation program. However, oocyte or 
ovarian cryopreservation can be the solitary option for young or 
unmarried female patients. Pre-pubertal children, on the 
grounds of ethical concerns regarding ovulation induction and 
oocyte retrieval, and women who cannot delay cancer 
treatment for the 2-4 week period necessary to perform 
ovulation induction, are not candidates for embryo 
cryopreservation.
Numerous non-neoplastic diseases are also treated with 
cytotoxic chemotherapy and radiation. In some of them, 
chemotherapy or radiation therapy is also used in extreme 
doses to ablate the preexisting bone marrow in HSCT. The 
indications for HSCT that extend beyond cancer now include 
some autoimmune diseases unresponsive to 
immunosuppressive therapy, diseases associated with 
genetically abnormal stem cells (hemoglobinopathies and 
enzyme deficiency disorders), and those associated with the 
deficiency of bone marrow stem cell products [18-23]. In this 
article, the current indications and techniques of fertility 
preservation will be reviewed from the gynecologic point of 
view, which mainly focuses on embryo, oocyte and ovarian 
cryopreservation. 
Chemotherapy- and radiotherapy-associated 
gonadal damage
Multiagent chemotherapy constitutes the basis of the 
modern cancer treatment. Ovaries, which are stocked with 
irreplaceable follicles, are extremely sensitive to most cytotoxic 
drugs [23,24]. The end result of the chemotherapy can range 
from damage to steroid-producing cells and/or oocytes of 
developing ovarian follicles (granulosa and theca cells), which 
can cause temporary amenorrhea, to apoptotic death of 
primordial follicles, which results in premature ovarian failure 
(POF). Ultrastructurally, ovarian exposure to chemotherapeutics 
is associated with marked follicle loss [25]. Factors that can 
potentially modify the risk of chemotherapy-induced ovarian 
failure are summarized in Table 1. 
Some chemotherapeutic agents are more commonly 
associated with permanent and irreversible gonadal damage, 
such as cyclophosphamide, chlorambucil, melphalan, busulfan, 
nitrogen mustard, procarbazine, ifosfamide, and thiotepa 
[23,26-30]. Among the moderately gonadotoxic agents are 
cisplatin and adriamycin, while bleomycin, actinomycin D, 
vincristine, methotrexate, and 5-fluorouracil are associated 
with mild or no gonadotoxicity (Table 2). Although there is 
limited evidence, paclitaxel may also be gonadotoxic, but this 
remains to be verified [31]. In Table 2, we classify the gonadal 
risk of commonly used chemotherapeutic agents after a 
comprehensive literature search [32].
Cyclophosphamide is the most recognized agent to cause 
damage to oocytes and granulosa cells. In a recent mouse 
study, cyclophosphamide-induced follicular damage occurred 
in a dose-dependent manner, even at low doses of 20 mg/kg 
[33]. Relative risk of POF was reported to be between 4 and 
9.3 in patients receiving cyclophosphamide [34,35]. During the 
last 10-15 years before the onset of menopause, primordial 
follicle loss is accelerated, which is reflected by a constant 
decrease in inhibin B levels and increase in follicle-stimulating 
hormone (FSH) levels. As a consequence, a smaller number of 
follicles that are more prone to cell division errors begin to grow 
each cycle, until menopause occurs, when the number of 
follicles falls below 1.000. Because of this, older women with a 
low primordial follicle pool have a higher risk of developing 
ovarian failure compared with young women with higher 
primordial follicle numbers. Consistent with this biological fact, 
earlier studies demonstrated that a cumulative 
cyclophosphamide dose of 5.2 g caused amenorrhea in 
women in their forties, 9.3 g in women in their thirties, and 20.4 
g in women in their twenties [27].
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Table 1. Factors that can modify the risk of chemotherapy-related 
gonadal failure
Age of the patient
Type of chemotherapeutic agents
Cumulative dose of alkylating agent
Concomitant use of abdominopelvic radiation therapy
Ovarian reserve
Schedule of implementationHematopoietic stem cell transplantation and the risk
of ovarian failure
There has been a dramatic increase in the survival of 
childhood cancer patients in recent years as a result of HSCT. 
On the contrary, high-dose chemotherapy used for conditioning 
before HSCT is extremely gonadotoxic, as has been consistently 
demonstrated in the previous studies. In the acute ovarian 
failure of childhood cancer survivor study [36] that included 
3309 childhood cancer survivors, exposure to more than 1000 
cGy ovarian radiation, age and treatment with cyclophosphamide 
or procarbazine were found as independent risk factors for 
development of POF in a multivariable logistic regression 
model. An important finding from the previous studies is that 
despite timely menarche, FSH concentrations show a tendency 
to rise to menopausal levels in children exposed to high-dose 
chemotherapy during the pre-pubertal period. This highlights 
the fact that occurrence of timely menarche does not guarantee 
preserved ovarian function. Brachet et al. [37] found that seven 
of 10 children with sickle cell disease receiving busulfan (14 or 
16 mg/kg) and cyclophosphamide (200 mg/kg) as 
preconditioning before HSCT developed POF. In the remaining 
three who had spontaneous puberty, serum FSH levels were 
very high at the time of puberty and slowly normalized 
thereafter. It is important to underline that three girls with 
ovarian function recovery differed from the seven others by the 
lower busulphan dose of the conditioning regimen they 
received (14 rather than 16 mg/kg). In a survey including 2819 
childhood cancer survivors, Sklar et al. [38] demonstrated that 
children who receive chemotherapy are at an extremely high 
risk for POF. In that study, the authors followed a cohort of 
children who were diagnosed with a malignancy before the age 
of 21 and were menstruating for at least five years afterward. 
The patients in the study group were compared with their 1065 
siblings. The median age at diagnosis was 7 (range, 0-20) and 
the median age at study was 29 (range, 18-50). The risk of 
developing ovarian failure was found 13.2-fold increased 
(range, 3.26-53.51) in those exposed to chemotherapy 
compared with their siblings. Although rare, resumption of 
menstruation years after the diagnosis of POF has also been 
reported [39].
How to assess post-chemotherapy gonadal function?
Most of the long-term follow-up studies assessing post-
chemotherapy ovarian function rely on menstruation as the 
only surrogate marker. Even though irregular menstruation or 
amenorrhea is highly likely to occur during the chemotherapy, 
even lasting for a considerable period after completion of the 
chemotherapy, many patients return to a pre-chemotherapy 
menstrual pattern. Hormonal reversal of a hypergonadotropic 
state that commonly occurs during the courses of chemotherapy 
to a normo-gonadotropic state may also be expected [40]. 
However, these women will always have a high risk of 
developing premature menopause during their later reproductive 
life. The fact that ovulation may occur despite loss of half of the 
follicular pool in rodents indicates that indirect assessment of 
ovarian reserve is an unreliable tool [23]. Ovarian reserve 
diminishes when FSH levels on the third day of the menstrual 
cycle are more than 12 IU/ml or estradiol is more than 75 pg/
ml, whereas ovarian failure is diagnosed when FSH is found as 
more than 40 mIU/ml in two measurements regardless of 
menstrual bleeding. Anti-Müllerian hormone (AMH) has recently 
been suggested as the most reliable marker of ovarian reserve 
[41]. In normal ovulating women, serum AMH levels are 
relatively constant during the menstrual cycle, serum 
concentrations of which show a rapid decline after 37 years. 
Anderson et al. [42] showed that compared with estradiol and 
FSH, AMH showed a more rapid and sustained change after 
chemotherapy. Moreover, the decrease in AMH occurred 
without a significant decrease in inhibin-B or increase in FSH 
concentrations. The severity and rapidity of the decrease in 
AMH concentrations compared with the partial decline in 
inhibin-B concentrations might reflect primordial and preantral 
follicles as the primary site of toxicity. This supports the 
observation that, even though there may be no clinical signs of 
ovarian failure, there is always damage to follicular reserve in 
proportion to the cumulative dose of chemotherapeutic agents 
that might not be detectable with routinely used laboratory 
tests. It is important to note that AMH is not influenced by 
confounding factors such as oral contraceptive use, day of 
menstrual cycle, or pregnancy. In a study assessing post-
chemotherapy ovarian function [43], despite the fact that all 
eight breast cancer study patients resumed menstruation after 
chemotherapy, three had irregular menstrual cycles, and five 
had undetectable inhibin-B levels or FSH values more than 50 
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Table 2. The degree of gonadotoxicity associated with chemo-
therapeutic agents 
High ovarian failure risk
   Cyclophosphamide
   Chlorambucil
   Melphalan
   Busulfan
   Nitrogen mustard
   Procarbazine
Moderate ovarian failure risk
   Cisplatin
   Adriamycin
   Paclitaxel
No or low ovarian failure risk
   Methotrexate
   5-Fluorouracil
   Vincristine
   Actinomycin D
   Bleomycin
Commonly used novel agents with as yet undetermined risk
   Irinotecan
   ImatinibIU/ml, suggesting some degree of impairment in ovarian 
reserve. Another study [44] found that, compared with FSH 
and inhibin-B, AMH constitutes the most sensitive predictor of 
ovarian reserve in women treated with chemotherapy for 
Hodgkin’s lymphoma. Furthermore, most women who reported 
one or more pregnancies had normal AMH levels for age at the 
time of the study. Similarly, it has been demonstrated that in 
breast cancer patients, AMH levels declined despite continued 
menstrual activity [45] and ovarian reserve markers were 
altered in those who seemingly had normal menstruation post-
chemotherapy [46]. Giuseppe et al. [47] assessed FSH, 
luteinizing hormone (LH), AMH, inhibin-B, and antral follicle 
count (AFC) and suggested the combination of AFC and AMH 
as having the best predictive value for ovarian reserve with a 
high sensitivity (83%) and specificity (88%) in patients treated 
with chemotherapy for Hodgkin’s lymphoma. In 25 patients 
with hematological malignancies, serum AMH concentrations 
were measured before and after cancer therapy and compared 
with normoovulatory controls. Despite having menstrual cycles 
and despite some patients conceiving spontaneously after 
chemotherapy, AMH levels and AFC were decreased, showing 
some degree of ovarian damage [48].
Radiotherapy
Ionizing radiation is a well-recognized cause of ovarian 
damage and permanent infertility. Gonadal damage occurs not 
only by direct exposure to radiation such as in the case of 
pelvic or low abdominal irradiation, but scattering of radiation 
may also cause considerable damage even if gonads are 
outside the radiation field. Radiation causes a dose-related 
reduction in the primordial follicle pool [49]. The human oocyte 
is extremely sensitive to radiation, and irradiation at ovarian 
dose >6 Gy usually causes irreversible ovarian failure [6]. 
Wallace et al. [50,51] demonstrated that <4 Gy is enough to 
destroy half of the oocyte population (LDL50 <4 Gy); however, 
very recently, using a revised mathematical model, the same 
authors suggested that the LDL50 of the oocytes was <2 Gy. 
Age at the time of exposure to radiotherapy, extent and type of 
radiation therapy (e.g. abdominal, pelvic external beam 
irradiation, intracavitary brachytherapy) and fractionation 
schedule are important prognostic indicators for development 
of ovarian failure [52-56]. In mice, radiation-induced 
chromosome damage in the oocytes was more evident in older 
compared with younger animals [54]. In general, irradiation is 
more toxic when given in single dose compared to fractionated 
doses. Stillman et al. [57] investigated the risk of ovarian failure 
among 182 long-term survivors of childhood cancers receiving 
abdominal radiotherapy. The mean follow-up was 16.4 years. 
Ovarian failure occurred in 68% of the patients when both 
ovaries were in the irradiation field, and in 14% of the patients 
when both ovaries were at the edge of the treatment field. 
None of the 122 children developed ovarian failure when one 
or both ovaries were outside the abdominal treatment field. In 
another study, failure in pubertal development or premature 
menopause was observed in 37 of 38 patients who received 
external abdominal irradiation during childhood for intra-
abdominal tumors in doses ranging from 20 to 30 Gy [58]. 
Sanders et al. [59] reported the probability of ovarian failure in 
patients receiving cyclophosphamide and total body irradiation 
for HSCT as 1.00 at one year. Failure in pubertal development 
may be the first sign of ovarian failure in these patients who 
received radiotherapy during childhood.
Indications for fertility preservation
As a result of improvements in cancer treatment and in the 
ability to detect tumors in their early stages by well-established 
screening programs for some cancers, life expectancy has 
strikingly increased. Furthermore, a cure is now possible for 
many childhood and adult cancers. Notably, cure rates 
approximate 90% in certain childhood cancers. A beneficial 
effect of cytotoxic treatment in various non-malignant diseases 
has also been repeatedly demonstrated. The idea of 
cryopreserving ovarian tissue is based on the finding that the 
ovarian cortex harbors primordial follicles that are more 
resistant to cryo-injury than are mature oocytes. Although the 
clinical indications for ovarian tissue cryopreservation are 
almost identical to those for the oocyte, there are fewer 
logistical restrictions in offering this technique. Despite the 
limited data on successful pregnancy rates, ovarian tissue 
cryopreservation has broader applications and, in theory, a 
greater fertility potential than oocyte cryopreservation because 
of the far larger number of oocytes preserved. Extending 
indications for ovarian tissue cryopreservation are listed below. 
A detailed list of indications is presented in Table 3 [60].
Cancers in children
Adult and childhood cancers are the most common 
indication for fertility preservation. Even though cancer is still 
the second leading cause of death in children, there has been 
remarkable improvement in the cure rates of many childhood 
cancers over the last three decades [1]. Among the most 
common cancers encountered during childhood are leukemia, 
Hodgkin’s and non-Hodgkin’s lymphomas, tumors of the 
central nervous system, soft tissue sarcomas, and renal 
tumors [61-66]. Acute lymphoblastic leukemia is the most 
common childhood cancer, with more than 2.100 new cases 
and 2,000 long-term survivors each year [66,67]. The five-year 
survival rate for all childhood cancers is approximately 80%, 
with a higher percentage for lymphomas (94%) and Wilms’ 
tumor (91%) [66-69]. Although many children survive cancer 
because of improved treatment modalities, they are certainly 
not immune to the gonadotoxic effects of various cancer 
treatments. Ovarian tissue cryopreservation may be the only 
acceptable method for any pre-pubertal or pre-menarchal 
female patients receiving chemotherapy, pelvic radiotherapy, 
HSCT, or oophorectomy for benign disease or prophylaxis 
[23]. The greatest benefit from the procedure is expected in 
children, since they have the highest number of primordial 
follicles [16]. With ovarian tissue freezing, no ovarian stimulation 
is needed; therefore, time restrictions for cancer therapy are 
fewer, and there is no risk of stimulating estrogen-sensitive 
cancer following ovarian stimulation [23]. Additionally, it avoids 
ethical concerns regarding ovarian stimulation and oocyte 
retrieval in children.
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The death rates from cancer in women have fallen, despite 
increased incidence during the 1990s. Approximately 8% of 
these cancers occur in reproductive aged women under the 
age of 40 years. Breast cancer, the most common cancer in 
women during the reproductive years, afflicted approximately 
216,000 women in the United States in 2004 [66]. The five-
year survival rate in breast cancer now approaches 90%. Most 
of the patients with breast cancer are subjected to 
cyclophosphamide-based gonadotoxic chemotherapy. In 
breast cancer, fortunately, unlike other malignant diseases, 
there is approximately a six-week hiatus between the initial 
surgery and chemotherapy. These patients may resort to 
assisted reproductive technologies during this time period. 
However, in theory, conventional ovarian stimulation protocols 
are thought to affect the growth of breast cancer as a result of 
supraphysiological estrogen concentrations. Novel stimulation 
protocols with tamoxifen and aromatase inhibitors are 
suggested as safer protocols in these patients. In addition, 
since occult ovarian metastasis is extremely rare, with the 
exception of stage IV disease and lobular carcinoma, these 
patients may resort to ovarian tissue cryopreservation [23,70]. 
Cancer of the cervix is a serious health problem afflicting 
500.000 women worldwide each year, with almost half of them 
under the age of 35 [71]. Patients with advanced stage disease 
and those with early stage disease who are found to have high 
risk factors receive pelvic or pelvic/paraaortic radiation therapy. 
Squamous cell cancer of the cervix, which is the most often 
encountered subtype, rarely metastasizes to the ovaries, 
whereas this may occur at a rate as high as 12% for 
adenocarcinoma and adenosquamous carcinoma. Ovarian 
transposition might be performed; however, success rates vary 
greatly because of damage to the vasculature during the 
procedure. Ovulation induction might be risky since there is 
risk of bleeding from the fragile cervix during oocyte retrieval. 
Ovarian tissue can be removed in selected patients for 
cryopreservation during primary cancer surgery. Another group 
of patients that are potential candidates for ovarian 
cryopreservation are those carrying BRCA I and II mutations. 
Despite the fact that the risk of peritoneal cancer cannot be totally 
eliminated in BRCA-positive patients, prophylactic oophorectomy 
is suggested as soon as childbearing is completed or by the age 
35-40 years to decrease the risk of ovarian and breast cancer 
[72,73]. Cortical pieces of ovarian tissue in those with a desire for 
fertility can be frozen for future use.
Autoimmune diseases
Autoimmune diseases can also affect women of reproductive 
age. There have been an increasing number of reports 
regarding the use of cytotoxic treatment, especially with 
cyclophosphamide, in autoimmune diseases, including 
systemic lupus erythematosus, steroid- resistant 
glomerulonephritis, Behçet’s disease, inflammatory bowel 
diseases, and pemphigus vulgaris [74-78]. Pieces of ovarian 
tissue may be harvested for possible future use in these 
patients in order to retain fertility. 
Experimental approaches
When the risk of ovarian involvement with cancer cells is 
high, some other experimental options may be considered. It 
has been possible to isolate primordial follicles from human 
ovarian tissue, but there has been no success in growing them 
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Table 3. Indications of fertility preservation
Cancer in children
   Hodgkin and non-Hodgkin lymphoma
   Leukemias
   Ewing’s sarcoma
   Neuroblastoma
   Wilms’ tumor
   Pelvic osteosarcoma
   Genital rhabdomyosarcoma
Breast cancer*
   Infiltrative ductal histological subtype
   Stage I–III
Cancer of the cervix
   Squamous cell carcinoma
   Adeno/adenosquamous carcinoma
Autoimmune and hematological diseases
   Systemic lupus erythematosus
   Behçet’s disease
   Steroid-resistant glomerulonephritis
   Inflammatory bowel disease
   Sickle cell disease
   Rheumatoid arthritis
   Progressive systemic sclerosis
   Pemphigus vulgaris
   Juvenile idiopathic arthritis
   Multiple sclerosis
   Autoimmune thrombocytopenia
   Aplastic anemia
Benign ovarian disease
   Endometriosis
   Benign ovarian lesions requiring repeated surgeries
Patients receiving pelvic radiation
   Solid organ tumors presenting in the pelvis
   Osteosarcoma
   Ewing’s sarcoma
   Tumors of the spinal cord
   Retroperitoneal sarcoma
   Rectal cancer
   Benign bone tumors
   Vanishing bone disease
Prophylactic oophorectomy
   BRCA-I and II germline mutation carriers
Hematopoietic stem cell transplantation
   Malignant diseases
   Genetic, hematological, and autoimmune disorders
Patients undergoing surgery for gynecological cancers**
* Ovarian cryopreservation is not recommended in advanced stage breast cancer. 
Compared to infiltrative ductal histologic subtype, infiltrative lobular breast cancer is 
more prone to metastasize to the ovaries in the early stages
**Fertility-preserving surgery includes conization or trachelectomy for early stage 
cervical cancer, fertility-preserving surgery for early stage ovarian cancer and hor-
monal treatment for endometrial cancerin vitro to get a healthy offspring [79]. Early stage preantral 
follicles can only be grown for brief periods of time in three-
dimensional culture systems. Another potential approach is 
xenografting human ovarian tissue in immunodeficient mice, 
where human follicles can be grown to antral stages and 
ovulated. However, the applicability of xenografting in the 
clinical setting has not been determined due to the risk of 
trans-species viral infections [80,81]. The mechanism of age-
related as well as chemo- or radiotherapy-induced loss in the 
ovarian germ cell population is proposed to be mediated by 
programmed cell death, i.e. apoptosis. Sphingosine-1-
phosphate (S1P), a bioactive sphingolipid metabolite, is an 
important lipid mediator and has many actions both inside and 
outside the cell. It was demonstrated that wild-type mice 
treated with S1P resisted both developmental and cancer 
therapy-induced apoptosis. Radiation-induced oocyte loss 
could be completely prevented by S1P therapy in wild-type 
mice, and no genomic damage in mice pretreated with S1P 
before receiving ionizing radiation could be demonstrated [82]. 
Another experimental approach has become a current issue 
with a report by Silber et al. [83], in which a transplantation of 
ovarian cortical tissue took place between 24-year-old 
monozygotic twins, one of whom suffered POF. The question 
arises of whether allogeneic ovarian transplantation is possible 
in the future for females with ovarian dysfunction following 
cancer therapies.
Conclusion
Fertility preservation requires a multimodality approach. 
Depending on a patient’s age, the type of cancer treated, time 
constraints, availability of a partner, and whether there is 
ovarian involvement, a different procedure may be needed for 
each cancer survivor facing treatment-related infertility. 
Physicians should take a comprehensive approach in 
counseling their patients regarding fertility preservation 
procedures.
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